Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
AN2 Therapeutics Inc (ANTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/07/2026: ANTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 79.7% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 01/07/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 29.32M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 3 | Beta -0.03 | 52 Weeks Range 1.00 - 1.55 | Updated Date 01/7/2026 |
52 Weeks Range 1.00 - 1.55 | Updated Date 01/7/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.13 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.35% | Return on Equity (TTM) -45.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -32600835 | Price to Sales(TTM) - |
Enterprise Value -32600835 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.11 | Shares Outstanding 27402024 | Shares Floating 17793778 |
Shares Outstanding 27402024 | Shares Floating 17793778 | ||
Percent Insiders 25.39 | Percent Institutions 39.36 |
Upturn AI SWOT
AN2 Therapeutics Inc
Company Overview
History and Background
AN2 Therapeutics Inc. was founded in 2018 with the goal of developing novel treatments for rare and severe infectious diseases. The company focuses on addressing significant unmet medical needs in areas where existing therapies are limited or ineffective. Its evolution has been marked by the progression of its lead drug candidate through clinical trials and strategic partnerships.
Core Business Areas
- Rare and Severe Infectious Diseases: AN2 Therapeutics is dedicated to developing therapeutics for rare and severe infectious diseases, particularly those that are difficult to treat and have limited therapeutic options. This includes antifungal and antiviral agents targeting life-threatening conditions.
Leadership and Structure
AN2 Therapeutics is led by a management team with experience in biotechnology and pharmaceutical development. The company operates as a clinical-stage biopharmaceutical company, structured to focus on drug discovery, development, and clinical trials.
Top Products and Market Share
Key Offerings
- AN2690 (Eperezumab): AN2690 is a novel, broad-spectrum oral antifungal agent currently in late-stage clinical development for the treatment of serious fungal infections, including azole-resistant invasive pulmonary aspergillosis. Competitors in the antifungal market include companies developing echinocandins (e.g., Merck, Pfizer) and other azole derivatives (e.g., Astellas Pharma, Pfizer). Specific market share data for AN2690 is not yet available as it is still in development.
Market Dynamics
Industry Overview
The infectious disease therapeutics market is driven by the emergence of drug-resistant pathogens, the increasing prevalence of immunocompromised patients, and the need for novel treatments for rare infections. Significant investment is being made in research and development to combat these challenges.
Positioning
AN2 Therapeutics is positioned as a developer of first-in-class or best-in-class therapies for rare and severe infectious diseases. Its focus on azole-resistant fungal infections, a growing area of concern, represents a key competitive advantage.
Total Addressable Market (TAM)
The TAM for serious fungal infections, particularly those that are azole-resistant, is substantial and growing. AN2 Therapeutics is positioned to capture a significant share of this market with its lead candidate, assuming successful clinical development and regulatory approval.
Upturn SWOT Analysis
Strengths
- Focus on a critical unmet medical need (azole-resistant fungal infections).
- Novel mechanism of action for its lead candidate.
- Experienced management team.
- Potential for orphan drug designation.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on a single lead candidate for current development.
- Significant capital requirements for clinical trials and regulatory approval.
Opportunities
- Increasing prevalence of drug-resistant fungal infections.
- Potential for strategic partnerships or acquisitions.
- Expanding the therapeutic indications for its lead candidate.
- Growing investor interest in rare disease treatments.
Threats
- Clinical trial failures or delays.
- Regulatory hurdles and approval challenges.
- Competition from other companies developing novel antifungal agents.
- Pricing and reimbursement challenges.
- Potential for adverse events or safety concerns.
Competitors and Market Share
Key Competitors
- Merck & Co. (MRK)
- Pfizer Inc. (PFE)
- Astellas Pharma Inc. (4503.T)
Competitive Landscape
AN2 Therapeutics' advantage lies in its focused approach to a specific, underserved niche within the antifungal market. However, it faces established players with extensive portfolios and significant resources. Its success hinges on demonstrating superior efficacy and safety for AN2690 compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Historically, AN2 Therapeutics' growth has been characterized by fundraising rounds to support its R&D activities and the progression of its drug candidates through preclinical and early clinical stages.
Future Projections: Future growth projections are heavily dependent on the successful completion of its Phase 3 clinical trials for AN2690 and subsequent regulatory approval. Analyst estimates, if available, would reflect potential market penetration and revenue forecasts.
Recent Initiatives: Recent initiatives would likely include advancements in clinical trial recruitment and execution, regulatory interactions, and potential strategic collaborations to further develop and commercialize its pipeline.
Summary
AN2 Therapeutics Inc. is a promising clinical-stage biopharmaceutical company targeting rare and severe infectious diseases. Its lead drug candidate, AN2690, shows potential in addressing azole-resistant fungal infections, a significant unmet medical need. The company's success hinges on navigating complex clinical trials and regulatory pathways, while facing competition from established pharmaceutical giants. Continued funding and successful clinical outcomes are critical for its future growth and value.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Industry Market Research Reports
- Financial News and Analysis Websites
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data accuracy and completeness are subject to the availability and reliability of underlying sources. Market share percentages are estimates and may vary. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AN2 Therapeutics Inc
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2022-03-25 | Co-Founder, CEO, President & Chairman of the Board Mr. Eric E. Easom | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | Website https://www.an2therapeutics.com |
Full time employees 22 | Website https://www.an2therapeutics.com | ||
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.